Youcare Pharmaceutical (SH:688658) Cai Jing Wang·2025-09-09 06:08Core Insights - The company, Yuyuan Pharmaceutical, held a performance briefing for the first half of 2025, highlighting its innovative drug projects that include small nucleic acids, mRNA vaccines, peptide drugs targeting viral membrane fusion inhibitors, small molecule drugs, and innovative traditional Chinese medicine [1] Drug Development Progress - The broad-spectrum coronavirus membrane fusion inhibitor peptide drug YKYY017 is currently in the II/III clinical stage [1] - The potential best-in-class ultra-long-acting siRNA lipid-lowering drug YKYY015 has completed the Ia clinical trial [1] - The ultra-long-acting antihypertensive drug YKYY029 targeting the AGT gene has received IND approval in both China and the United States, with domestic phase I clinical trials progressing steadily [1] - The company is also advancing a potential best-in-class functional cure for hepatitis B and other innovative drugs, including RSV membrane fusion inhibitor peptide YKYY018 and therapeutic mRNA lyophilized vaccine YKYY031 [1] Business Development and Regulatory Updates - The company has intensified its global business development efforts this year by participating in international conferences [1] - In response to investor inquiries about the progress of three new drug applications, the management provided updates on traditional Chinese medicine innovative drugs, which are currently in various stages of development [1] - The management addressed concerns regarding the slow progress of the CT102 clinical trial, stating that it has completed the IIa clinical trial and is currently analyzing data to formulate subsequent clinical trial plans and strategies [1]